Results 11 to 20 of about 25,109 (253)

Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression

PLoS ONE, 2022
ErbB3 (HER3), a member of the HER family, is overexpressed in various cancers and plays an important role in cell proliferation and survival. Certain HER3 mutations have also been identified as oncogenic drivers, making them potential therapeutic targets.
Kumiko Koyama, Hirokazu Ishikawa, Manabu Abe, Yoshinobu Shiose, Suguru Ueno, Yang Qiu, Kenji Nakamaru, Masato Murakami   +7 more
doaj   +4 more sources

Cellular effects of HER3-specific affibody molecules. [PDF]

PLoS ONE, 2012
Recent studies have led to the recognition of the epidermal growth factor receptor HER3 as a key player in cancer, and consequently this receptor has gained increased interest as a target for cancer therapy.
Lovisa Göstring, Magdalena Malm, Ingmarie Höidén-Guthenberg, Fredrik Y Frejd, Stefan Ståhl, John Löfblom, Lars Gedda   +6 more
doaj   +5 more sources

HER3 signaling and targeted therapy in cancer

Oncology Reviews, 2018
ERBB family members including epidermal growth factor receptor (EGFR) also known as HER1, ERBB2/HER2/Neu, ERBB3/HER3 and ERBB4/HER4 are aberrantly activated in multiple cancers and hence serve as drug targets and biomarkers in modern precision therapy ...
Rosalin Mishra, Hima Patel, Samar Alanazi, Long Yuan, Joan T. Garrett   +4 more
doaj   +4 more sources

Immuno-PET Imaging of HER3 in a Model in which HER3 Signaling Plays a Critical Role. [PDF]

PLoS ONE, 2015
HER3 is overexpressed in various carcinomas including colorectal cancer (CRC), which is associated with poor prognosis, and is involved in the development of therapy resistance.
Qinghua Yuan, Takako Furukawa, Takahiro Tashiro, Kouki Okita, Zhao-Hui Jin, Winn Aung, Aya Sugyo, Kotaro Nagatsu, Hiroko Endo, Atsushi B Tsuji, Ming-Rong Zhang, Takashi Masuko, Masahiro Inoue, Yasuhisa Fujibayashi, Tsuneo Saga   +14 more
doaj   +4 more sources

EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody–Drug Conjugate HER3–DXd

Cancer Research, 2021
EGFR inhibition leads to increased HER3 membrane expression and promotes HER3–DXd ADC internalization and efficacy, supporting the clinical development of the EGFR inhibitor/HER3–DXd combination in EGFR-mutant lung cancer.
Heidi M. Haikala, T. Lopez, J. Köhler, P. Eser, Man Xu, Qing Zeng, Tyler J. Teceno, K. Ngo, Yutong Zhao, E. Ivanova, Arrien A. Bertram, B. Leeper, E. Chambers, Anika E. Adeni, Luke J. Taus, M. Kuraguchi, P. Kirschmeier, Channing Yu, Y. Shiose, Y. Kamai, Yang Qiu, C. Paweletz, P. Gokhale, P. Jänne   +23 more
semanticscholar   +3 more sources

HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy

Journal of Clinical Oncology, 2023
PURPOSE Patritumab deruxtecan, or HER3-DXd, is an antibody-drug conjugate consisting of a fully human monoclonal antibody to human epidermal growth factor receptor 3 (HER3) attached to a topoisomerase I inhibitor payload via a stable tetrapeptide-based ...
H. Yu, Y. Goto, H. Hayashi, E. Felip, J. Chih-Hsin Yang, Martin Reck, K. Yoh, Se-Hoon Lee, L. Paz-Ares, B. Besse, P. Bironzo, Dong-Wan Kim, M. Johnson, Yi‐Long Wu, Thomas John, S. Kao, T. Kozuki, E. Massarelli, Jyoti D. Patel, Egbert F. Smit, K. Reckamp, Qian Dong, Pomy Shrestha, P. Fan, P. Patel, Andrea Sporchia, D. Sternberg, D. Sellami, P. Jänne   +28 more
semanticscholar   +1 more source

A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells

Scientific Reports, 2021
HER3 is a member of the EGF receptor family and elevated expression is associated with cancer progression and therapy resistance. HER3-specific T-cell engagers might be a suitable treatment option to circumvent the limited efficacy observed for HER3 ...
Nadine Aschmoneit, Sophia Steinlein, Lennart Kühl, Oliver Seifert, Roland E. Kontermann   +4 more
doaj   +1 more source

Molecular Pathways: HER3 Targeted Therapy [PDF]

Clinical Cancer Research, 2014
Abstract The HER family of receptor tyrosine kinases, including EGF receptor (EGFR), HER2, HER3, and HER4, transduce growth-promoting signals in response to ligand binding to their extracellular domains (ECD). This family is deregulated in numerous cancers, with mutations in EGFR and HER2 often serving as “driver” events to activate key ...
Kinisha, Gala, Sarat, Chandarlapaty
openaire   +2 more sources

Human epidermal growth factor receptor 3 serves as a novel therapeutic target for acral melanoma

Cell Death Discovery, 2023
Acral melanoma (AM) is a rare, life-threatening skin cancer. Since AM bears unique features, existing therapies for other types of malignant melanomas have limited effects and the establishment of effective treatments for AM is strongly desired.
Yuka Tanaka, Takamichi Ito, Yumiko Kaku-Ito, Keiko Tanegashima, Gaku Tsuji, Makiko Kido-Nakahara, Yoshinao Oda, Takeshi Nakahara   +7 more
doaj   +1 more source

Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3–Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3–Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial

Journal of Clinical Oncology, 2023
PURPOSE Human epidermal growth factor receptor 3 (HER3) is broadly expressed in breast cancer; high expression is associated with an adverse prognosis. Patritumab deruxtecan (HER3-DXd) is an investigational HER3-targeted antibody-drug conjugate that is ...
I. Krop, N. Masuda, T. Mukohara, Shunji Takahashi, T. Nakayama, K. Inoue, H. Iwata, Yutaka Yamamoto, Ricardo H. Alvarez, Tatsuya Toyama, M. Takahashi, Akihiko Osaki, S. Saji, Y. Sagara, J. O'Shaughnessy, S. Ohwada, K. Koyama, Tatsuya Inoue, Li Li, P. Patel, Joseph Mostillo, Yoshimi Tanaka, D. Sternberg, D. Sellami, K. Yonemori   +24 more
semanticscholar   +1 more source